drugset / Trial / NCT01732874

DHA Supplementation for Lactating Mothers

NCT01732874 ↗

Phase 1/2 Completed 27 enrolled Children's Hospital Medical Center, Cincinnati
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this research study is to find out whether preterm infants are receiving enough of the essential and long chain fatty acids important for brain development and immune function. Our current intravenous (IV) fats do not contain the long chain fatty acids and different milk sources have different compositions. We would like to evaluate lactating mothers dietary intake and breastmilk level of fatty acid status by doing an analysis of their blood and breastmilk samples after they have been supplemented with a currently used fatty acid supplement (DHA- Martek Biosciences, now known as Dutch State Mines (DSM) Nutritional Lipid) The DHA supplement is available over the counter. The information learned from this research study may benefit other mothers and babies in the future. The information could help make sure premature babies are receiving the right nutrients they need for appropriate growth and development.

Timeline

Start
2013-05
Primary completion
2018-07-16
Completion
2018-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Expecta Other / unclassified 200 mg Oral
Subject Expecta Other / unclassified 1 g Oral

Indications

No indication recorded.